Lepu medical Antibody tests
Lepu Medical Technology (Beijing) Co., Ltd. was established in 1999, and went public in 2009. Lepu Medical is specialized in developing, manufacturing and distributing high-tech medical devices and equipment. Today, Lepu Medical has grown into a global leading company with 32 primary subsidiaries worldwide in the fields of cardiovascular, neurovascular and peripheral vascular interventions, structural heart diseases, surgical cardiology, cardiac rhythm management, critical care, anesthesia, hematodialysis, general surgery, orthopedics and in vitro diagnostics with products include coronary stents, dilatation balloon catheters, interventional accessories, occlusion devices, mechanical heart valves, pacemakers, dialyzers, anesthesia products, ECG devices, patient monitors, oximeters, surgical staplers, orthopedic products, in vitro diagnostic products and angiography DSA systems.
Antibodies will be secreted after virus invasion. Immunoglobulin M (IgM) comes out first, acting as the early sign of infection. Immunoglobulin G (IgG) comes out later, arising a more specific and stronger reaction against the virus.
220 clinical samples based on the nucleic acid detection method (PCR) test results were obtained, including 93 positive and 127 negative samples. The SARS-CoV-2 Antibody Test was compared with nucleic acid method (PCR) using the collected clinical samples. The results were summarized in the table below: